NCT07274631

Brief Summary

Chronic inflammatory pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, cystic fibrosis (CF), primary ciliary dyskinesia (PCD) and interstitial lung diseases (ILD) are characterised by lung inflammation and remodelling. Clinical, functional, microbiological, biological, pathological and prognostic features are highly variable and heterogeneous. Several phenotypes have been described within the same pathology, as similar phenotypic traits between different pathologies, or the coexistence of components of several diagnoses in the same patient, suggesting shared underlying mechanisms that could represent new therapeutic targets, beyond the initial medical diagnosis. The objectives of this prospective study are to analyze the phenotypic characteristics (clinical, demographic, biological, morphological, pathological, and microbiological characteristics) together with respiratory exposures and underlying mechanisms involving airway epithelium and inflammation processes in a cohort of patients diagnosed with asthma, COPD, bronchiectasis, CF, PCD and ILD.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
470

participants targeted

Target at P75+ for all trials

Timeline
175mo left

Started Sep 2025

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress4%
Sep 2025Sep 2040

First Submitted

Initial submission to the registry

June 10, 2025

Completed
3 months until next milestone

Study Start

First participant enrolled

September 15, 2025

Completed
3 months until next milestone

First Posted

Study publicly available on registry

December 10, 2025

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 15, 2030

Expected
10 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 15, 2040

Last Updated

February 20, 2026

Status Verified

February 1, 2026

Enrollment Period

5 years

First QC Date

June 10, 2025

Last Update Submit

February 18, 2026

Conditions

AsthmaChronic Obstructive Pulmonary DiseaseBronchiectasisCystic FibrosisPrimary Ciliary Dyskinesia

Keywords

Chronic obstructive pulmonary diseaseAsthmaBronchiectasisCystic fibrosisPrimary ciliary dyskinesiaAirway microbiotaAirway epitheliumRemodelingExposome

Outcome Measures

Primary Outcomes (1)

  • pheno-endotypes of inflammatory respiratory disease

    Number of subjects in each of the identified pheno-endotypes of inflammatory respiratory disease

    Baseline

Secondary Outcomes (10)

  • Forced expiratory volume in one second ( FEV1)

    10 years

  • Forced Vital Capacity ( FVC )

    10 years

  • Total Lung Capacity (TLC)

    10 years

  • Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)

    10 years

  • 6 minutes walking distance

    10 years

  • +5 more secondary outcomes

Interventions

Non applicableOTHER

Non applicable

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patients (≥18 years old) followed for chronic inflammatory respiratory diseases (asthma, COPD, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, or interstitial lung diseases) at the Respiratory Medicine Department of CHU Reims. Healthy control subjects without diagnosed respiratory disease will also be included.

You may qualify if:

  • Age ≥ 18 years
  • Follow-up for one of the following conditions: asthma, COPD, bronchiectasis (DDB), cystic fibrosis (CF), primary ciliary dyskinesia (PCD), or interstitial lung diseases (ILD)
  • Healthy volunteers (controls)

You may not qualify if:

  • Subjects protected by law (e.g., legal incapacity)
  • Any condition preventing informed consent or participation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chu Reims

Reims, 51092, France

RECRUITING

MeSH Terms

Conditions

Pulmonary Disease, Chronic ObstructiveAsthmaBronchiectasisCystic FibrosisCiliary Motility Disorders

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsBronchial DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesPancreatic DiseasesDigestive System DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesInfant, Newborn, DiseasesOtorhinolaryngologic DiseasesCiliopathiesAbnormalities, MultipleCongenital Abnormalities

Central Study Contacts

Jeanne-Marie PEROTIN-COLLARD

CONTACT

03 10 73 67 63jmperotin-collard@chu-reims.fr

Gaëtan DESLEE

CONTACT

03 26 78 76 11gdeslee@chu-reims.fr

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
10 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 10, 2025

First Posted

December 10, 2025

Study Start

September 15, 2025

Primary Completion (Estimated)

September 15, 2030

Study Completion (Estimated)

September 15, 2040

Last Updated

February 20, 2026

Record last verified: 2026-02

Locations

FR(1)